Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer

Akito Hata1, Daijiro Harada3, Chiyuki Okuda1, Reiko Kaji1, Yoshio Masuda2, Yoshika Takechi4, Toshiyuki Kozuki3, Naoyuki Nogami3 and Nobuyuki Katakami1

1Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan
2Department of Pharmacy, Kobe City Medical Center General Hospital, Kobe, Japan
3Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
4Department of Pharmacy, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan

Correspondence to: Akito Hata, email: akito.hata@hotmail.com

Keywords: docetaxel; ramucirumab; febrile neutropenia; pegylated-granulocyte-colony stimulating factor

ABSTRACT

Purpose: The aim of our study was to evaluate the efficacy and safety of docetaxel plus ramucirumab with primary prophylactic pegylated (PEG)-granulocyte-colony stimulating factor (G-CSF) for pretreated non-small cell lung cancer (NSCLC).

Results: Sixty-one pretreated NSCLC patients underwent docetaxel plus ramucirumab. Primary prophylactic PEG-G-CSF was performed in 52 (85%) patients (prophylactic group). No febrile neutropenia (FN) (0%) was confirmed in 52 prophylactic group patients, whereas FN was observed in 3 (33%) of 9 non-prophylactic group patients. Among prophylactic group, median lines of prior therapy was 2 (range, 1–9). Median cycles of docetaxel plus ramucirumab was 3 (range, 1–25) (9 and 3 cases moved to ramucirumab and docetaxel monotherapies, respectively). Response rate and disease control rate were 30.8% and 73.1%, respectively. Median progression-free survival was 4.5 (95% confidence interval [CI], 3.0–6.6) months. Median overall survival was 11.4 (95% CI, 8.0–13.9) months. Six (11.5%) patients had grade 3/4 neutropenia. Observed grade 3 (incidence ≥10%) adverse event (AE) was oral mucositis (13.5%). There were no grade 4/5 non-hematological AEs.

Conclusions: Our study demonstrated the efficacy and safety of docetaxel plus ramucirumab with PEG-G-CSF in clinical practice. Primary prophylactic PEG-G-CSF could markedly reduce incidence of FN.

Methods: We retrospectively reviewed medical records of pretreated NSCLC cases who had received docetaxel plus ramucirumab in our departments.

INTRODUCTION

Systemic chemotherapy is the standard treatment for metastatic advanced non-small cell lung cancer (NSCLC). Current revolutionally advancement of molecular targeted therapies and immunotherapies has improved prognosis of NSCLC patients. Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) or anaplastic lymphoma kinase (ALK)-TKIs exhibited remarkable efficacies over platinum-doublet cytotoxic chemotherapies in patients harboring EGFR gene mutations or ALK gene fusions [1–5]. Furthermore, pembrolizumab, anti-programmed death-1 (PD-1) antibody has demonstrated superior overall survival over platinum-doublets in first-line setting of NSCLC patients with PD-ligand 1 (PD-L1) tumor proportion score ≥50% [6]. Despite an
initial dramatic response and durable progression-free survival (PFS) using these agents, progressive disease (PD) is inevitable in most patients. Therefore, second-line chemotherapy is still important to salvage patients after PD on a first-line chemotherapy.

Docetaxel was the standard regimen in second-line chemotherapy for pretreated NSCLC. Although a lot of agents, or those in combination with docetaxel, were compared to docetaxel monotherapy, no agents or combination therapies proved superior to docetaxel monotherapy. Eventually, immunotherapies with PD-1/PD-L1 inhibitors such as nivolumab, pembrolizumab, and atezolizumab have shown superior survival benefit over docetaxel monotherapy [7–10]. These immunotherapies give a strong survival benefit to responders, but disease control rate is relatively low, and early death is a serious concern in non-responders [11].

Ramucirumab is a fully human immunoglobulin G1 monoclonal antibody that binds with high affinity to vascular endothelial growth factor (VEGF) receptor-2, preventing VEGF binding and activation [12]. A randomized, phase III REVEL trial demonstrated that additional ramucirumab to docetaxel prolonged OS in NSCLC patients who had progressed after first-line platinum-based therapy [13]. In this trial, superior response rate (RR) and PFS translated to OS benefit with a high disease control rate (DCR). A similarly designed Japanese randomized phase II trial comparing docetaxel plus ramucirumab with docetaxel monotherapy showed that effectiveness of additional ramucirumab was comparable to those of REVEL study [14]. On the other hand, a safety concern was suggested. Febrile neutropenia (FN) was confirmed in 34% of these Japanese patients in docetaxel plus ramucirumab arm. This high incidence of FN presents an important clinical problem for docetaxel plus ramucirumab, used routinely in Japanese clinical practice.

The American Society of Clinical Oncology practice guideline recommends primary prophylactic granulocyte-colony stimulating factor (G-CSF) when the risk of FN is approximately 20% or higher [15]. We thus consider primary prophylactic G-CSF to be suitable in docetaxel plus ramucirumab therapy for Japanese patients. Pegylated (PEG)-G-CSF demonstrated reduction of FN incidence administered once a cycle in many types of cancers. PEG-filgrastim is a polyethylene glycol-derived form of filgrastim. Based on the features of PEG-conjugated proteins, PEG-filgrastim was designed to prolong the half-life of filgrastim and to decrease the number of injections. A Japanese double-blind, placebo-controlled, randomized phase III trial of PEG-filgrastim in 343 breast cancer patients receiving docetaxel and cyclophosphamide chemotherapy showed that the incidence of FN was significantly lower in the PEG-filgrastim group than in the placebo group (1.2% vs. 68.8%, P < 0.001) [16]. In NSCLC patients, incidence of FN could also be reduced by PEG-G-CSF.

Based on the above background, we actively use primary prophylactic PEG-G-CSF in our clinical practice on docetaxel plus ramucirumab therapy. The aim of this retrospective study was to evaluate the efficacy and safety of docetaxel plus ramucirumab with primary prophylactic PEG-G-CSF support for pretreated NSCLC in Japanese clinical practice.

**RESULTS**

**Patient characteristics**

Study flow chart is shown in Figure 1. Between June 2013 and April 2018, 61 pretreated NSCLC patients received docetaxel plus ramucirumab at our departments (31 Department of Medical Oncology, Kobe City Medical Center General Hospital [KCGH] and 30 Department of Thoracic Oncology, Shikoku Cancer Center [SCC]). We fully evaluated the efficacy and safety of docetaxel plus ramucirumab in 52 (85%) patients receiving primary prophylactic PEG-G-CSF (prophylactic group). In

![Figure 1: Study flow chart.](image-url)
remaining 9 (15%) patients without primary prophylactic PEG-G-CSF (non-prophylactic group), incidence of FN was mainly examined. Patient characteristics are shown in Table 1. Among prophylactic group, median age was 64 (range, 47–79). Male (65%), smoker (73%), and good Eastern Cooperative Oncology Group performance status (PS) (0/1) (87%) were dominant. Fifteen (29%) were EGFR mutant (no ALK-fusioned). Median number of prior regimens was 2 (range, 1–8). Prior bevacizumab was administered in 21 (40%) patients. Prior EGFR-TKIs were prescribed in all 15 EGFR-mutant patients, and two wild-type patients underwent erlotinib. All patients received docetaxel plus ramucirumab after failure of platinum-doublets. Prior taxanes were administered in 28 (54%) patients. Patient characteristics of non-prophylactic group were similar to prophylactic group.

### Incidence of febrile neutropenia

No FN (0%: 95% confidence interval [CI], 0–6.9%) was confirmed in 52 prophylactic group patients, whereas FN was observed in 3 (33%: 95% CI, 7.5–70.1%) of 9 non-prophylactic group patients.

### Efficacy in prophylactic group

One (1.9%) complete response (CR), 15 (28.8%) partial response (PR), 22 (42.3%) stable disease (SD), 12

---

### Table 1: Patient characteristics

| Characteristics                  | Prophylactic group (n = 52) | Non-prophylactic group (n = 9) |
|----------------------------------|----------------------------|-------------------------------|
| Median age, years (range)        | 64 (47–79)                 | 67 (61–76)                   |
| Gender                           |                            |                               |
| Male                             | 34 (65%)                   | 5 (56%)                      |
| Female                           | 18 (35%)                   | 4 (44%)                      |
| Smoking history                  |                            |                               |
| Never                            | 14 (27%)                   | 4 (44%)                      |
| Ever                             | 38 (73%)                   | 5 (56%)                      |
| Performance status               |                            |                               |
| 0/1                              | 3/42 (87%)                 | 1/8 (100%)                   |
| 2/3                              | 5/2 (13%)                  | 0/0 (0%)                     |
| Histology                        |                            |                               |
| Adenocarcinoma                   | 35 (67%)                   | 7 (78%)                      |
| Squamous/Large                   | 16/1 (33%)                 | 2/0 (22%)                    |
| EGFR mutation                    |                            |                               |
| Mutant                           | 15 (29%)                   | 3 (33%)                      |
| Wild                             | 37 (71%)                   | 6 (67%)                      |
| Prior regimens, median (range)   | 2 (1–8)                    | 1 (1–9)                      |
| Prior bevacizumab                |                            |                               |
| Administered                     | 21 (40%)                   | 3 (33%)                      |
| None                             | 31 (60%)                   | 6 (67%)                      |
| Prior EGFR-TKIs                  |                            |                               |
| Administered                     | 17 (33%)                   | 3 (33%)                      |
| None                             | 35 (67%)                   | 6 (67%)                      |
| Prior platinum doublets          |                            |                               |
| Administered                     | 52 (100%)                  | 9 (100%)                     |
| None                             | 0 (0%)                     | 0 (0%)                       |
| Prior taxanes                    |                            |                               |
| Administered                     | 28 (54%)                   | 5 (56%)                      |
| None                             | 24 (46%)                   | 4 (44%)                      |

Abbreviations: EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
(23.1%) PD, and 2 (3.8%) not evaluable were confirmed, resulting in RR of 30.8% (95% CI, 18.7–45.1%) and DCR of 73.1% (95% CI, 60.4–86.4%), respectively. The median PFS was 4.5 (95% CI, 3.0–6.6) months (Figure 2), and the median OS was 11.4 (95% CI, 8.0–13.9) months (referential results because docetaxel plus ramucirumab was administered at multiple lines).

Safety in prophylactic group

Table 2 summarizes adverse events (AEs) in 52 patients with prophylactic PEG-G-CSF. Hematological AEs ≥grade 3: 6 (11.5%) neutropenia; 3 (5.8%) anemia; and 2 (3.8%) thrombocytopenia were recorded. Non-hematological AEs ≥grade 3: 7 (13.5%) oral mucositis; 4 (7.7%) anorexia; 2 (3.8%) interstitial lung disease (ILD); 1 allergy (1.9%); 1 (1.9%) hand-foot syndrome; and 1 (1.9%) neurotoxicity were observed. Ramucirumab-associated AEs ≥grade 3: 1 (1.9%) brain tumor hemorrhage; 1 (1.9%) gastrointestinal bleeding; and 1 (1.9%) venous thrombosis were found. Neither grade 4 nor 5 non-hematological AEs were confirmed.

Administration of docetaxel and ramucirumab in prophylactic group

Docetaxel was administered at 60 mg/m² in 44 (85%) patients and at 50 mg/m² in 8 (15%) patients (dose reduction was performed at physicians’ discretion). Median cycles of docetaxel and ramucirumab was 3 (range, 1–25). Fourteen (29%) patients received more than 6 cycles of the therapy. Three (6%) and 9 (17%) patients moved to docetaxel and ramucirumab monotherapy, respectively, because of intolerable toxicities or physicians’ discretion.

Table 3 shows data on three patients who suffered from FN. These three patients did not receive prophylactic PEG-G-CSF. All patients had good PS (ECOG PS: 1), but experienced grade 4 neutropenia. Two of 3 patients were aged ≥75. Prior bevacizumab was administered in one patient. Two patients were collected from SCC and one was from KCGH.

Characteristics of elderly patients aged ≥75

Table 4 shows data on elderly patients aged ≥75 (n = 11). Initial dose of docetaxel was reduced to 50 mg/m² in four cases at physicians’ discretion. No FN was confirmed in all nine cases receiving PEG-G-CSF support, whereas two cases without PEG-G-CSF had FN. Four of these 11 patients achieved PR. AEs ≥grade 2: 6 mucocitis; 5 anemia; 3 thrombocytopenia; 2 neutropenia; 1 anorexia; 1 malaise; 1 hand-foot syndrome; 1 ILD; and 1 hypertension were observed.

DISCUSSION

To the best of our knowledge, this is the first report to investigate the efficacy and safety of docetaxel plus ramucirumab with primary prophylactic PEG-G-CSF support in pretreated NSCLC. Our study demonstrated 0% of FN incidence by primary prophylactic PEG-G-CSF support in docetaxel plus ramucirumab therapy for Japanese patients with pretreated NSCLC. FN incidence of REVEL and Japanese phase II study in docetaxel plus ramucirumab were 13.3% and 34.2%, respectively [13, 14]. Our study suggests high potency of primary prophylactic PEG-G-CSF support to prevent FN in docetaxel plus ramucirumab therapy.

Characteristics of febrile neutropenia patients

Figure 2: Progression-free survival.
The RR and DCR in prophylactic group were 30.8% and 73.1%, respectively. These results were comparable to REVEL (23% and 64%) and Japanese phase II study (28.5% and 78.9%) in each docetaxel plus ramucirumab arm [13, 14]. The median PFS was 4.5 months, which was also similar to that of REVEL (4.5 months) and Japanese phase II study (5.2 months) [13, 14]. Although our study population included relatively many heavily pretreated patients, primary prophylactic PEG-G-CSF support improved the safety while maintaining the effectiveness in docetaxel plus ramucirumab therapy.

Neither grade 4 nor 5 non-hematological AEs were confirmed, owing to primary prophylactic PEG-G-CSF support, with neutropenia ≥grade 3 only observed in 6 (11.5%) patients. Some ramucirumab-associated AEs ≥grade 3 were confirmed: 1 (1.9%) brain tumor hemorrhage; 1 (1.9%) gastrointestinal bleeding; and 1 (1.9%) venous thrombosis. Incidences of these VEGF-associated AEs were not high, compared to historical data of docetaxel plus ramucirumab therapy [13, 14]. Oral mucositis was the only non-hematological AEs ≥grade 3 observed more than 10% of patients. Physicians should beware of this AE for heavily pretreated patients receiving docetaxel plus ramucirumab therapy in clinical practice.

The study populations included 11 patients aged ≥75. No FN was confirmed in all nine cases receiving PEG-G-CSF support, whereas two cases without PEG-G-CSF had FN. Moreover, four of these nine patients achieved PR, and general AEs were tolerable. Although docetaxel dose was reduced to 50 mg/m² in a 76 year-old male, FN was confirmed with grade 4 neutropenia. Administration of PEG-G-CSF seems a better option than dose reduction. PEG-G-CSF support might be much more reasonable for elderly patients receiving docetaxel plus ramucirumab. Indeed, a multicenter phase II trial to evaluate the efficacy and safety of docetaxel plus ramucirumab with PEG-G-CSF support for chemo-naïve elderly NSCLC patients is ongoing (West Japan Oncology Group 9416L).

Our study was retrospective and small sample size, including several limitations. Regular measurement of temperature was not routinely carried out. FN incidence might have been estimated lower. However, FN is generally considered as an oncology emergency, and clinically relevant FN must have been detected. Tumor

| Table 2: Adverse events in patients with prophylactic PEG-G-CSF (n = 52) |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Adverse event   | Grade 1/2 (n)   | Grade 3/4 (n)   | ≥ grade 3 (%)   | All (%)         |
| Hematological   |                 |                 |                 |                 |
| Neutropenia     | 10              | 6               | 11.5            | 30.8            |
| Anemia          | 26              | 3               | 5.8             | 55.8            |
| Thrombocytopenia| 12              | 2               | 3.8             | 26.9            |
| Febrile neutropenia | -          | 0               | 0               | 0               |
| Non-hematological|                |                 |                 |                 |
| Anorexia        | 23              | 4               | 7.7             | 51.9            |
| Malaise         | 18              | 0               | 0               | 34.6            |
| Oral mucositis  | 19              | 7               | 13.5            | 50.0            |
| Interstitial pneumonia | 0        | 2               | 3.8             | 3.8             |
| Neurotoxicity   | 4               | 1               | 1.9             | 9.6             |
| Allergy         | 0               | 1               | 1.9             | 1.9             |
| Hand-foot syndrome | 0          | 1               | 1.9             | 1.9             |
| Ramucirumab-associated |        |                 |                 |                 |
| Hemoptyis       | 3               | 0               | 0               | 5.8             |
| Epistaxis       | 7               | 0               | 0               | 13.5            |
| Hypertension    | 7               | 0               | 0               | 13.5            |
| Proteinuria     | 14              | 0               | 0               | 26.9            |
| Venous thrombosis | 0             | 1               | 1.9             | 1.9             |
| Brain hemorrhage| 0               | 1               | 1.9             | 1.9             |
| Gastrointestinal bleeding | 0    | 1               | 1.9             | 1.9             |

No grade 4/5 adverse events
Abbreviations: PEG-G-CSF, pegylated-granulocyte-colony stimulating factor.
response and PFS were evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST), but durations of CT scans depended on doctors in charge. These variable durations could be a bias of our study. However, purpose of chemotherapy for pretreated patients was not response, but living longer with better quality of life (QOL). Subset analysis of the Japanese phase II trial suggested a possible association between FN occurrence and QOL deterioration [14, 17]. PEG-G-CSF support could maintain QOL in pretreated patients receiving docetaxel plus ramucirumab therapy.

In conclusion, our study demonstrated 0% of FN incidence by primary prophylactic PEG-G-CSF support in docetaxel plus ramucirumab therapy for Japanese patients with pretreated NSCLC. Primary prophylactic PEG-G-CSF could markedly reduce incidence of FN. Our study populations included many heavily pretreated patients, while docetaxel plus ramucirumab showed notable efficacy and safety. Further studies are warranted to confirm the effectiveness of primary prophylactic PEG-G-CSF support in docetaxel plus ramucirumab therapy.

### Table 3: Characteristics of febrile neutropenia patients (n = 3)

| Age | Sex | His | PS | EGFR  | Smoking | DOC dose | PEG-G-CSF | Line of DOC + RAM | Prior Bev | Institute | Response | PFS | Adverse events (grade ≥2) |
|-----|-----|-----|----|-------|---------|----------|-----------|------------------|-----------|-----------|----------|-----|--------------------------|
| 63  | M   | Ad  | 1  | Wild  | Former  | 60       | -         | 2nd              | +         | SCC       | SD       | 1.9 | Neutropenia (G4)         |
| 75  | M   | Ad  | 1  | Wild  | Former  | 60       | -         | 2nd              | -         | SCC       | PD       | 1.8 | Neutropenia (G4), anemia (G2), thrombocytopenia (G2), anorexia (G2), mucositis (G2) |
| 76  | M   | Ad  | 1  | L858R | Never   | 50       | -         | 4th              | -         | KCGH      | NE       | 1.0 | Neutropenia (G4), mucositis (G2) |

Abbreviations: His, histology; PS, performance status; EGFR, epidermal growth factor receptor; DOC, docetaxel; PEG-G-CSF, pegylated-granulocyte-colony stimulating factor; RAM, ramucirumab; Bev, bevacizumab; SCC, Shikoku Cancer Center; KCGH, Kobe City Medical Center General Hospital; PFS, progression-free survival; M, male; F, female; Ad, adenocarcinoma; SD, stable disease; PD, progressive disease; NE, not evaluable; G, grade; ILD, interstitial lung disease.

### Table 4: Characteristics of elderly patients aged ≥75 (n = 11)

| Age | Sex | His | PS | EGFR  | Smoking | DOC dose | PEG-G-CSF | Line of DOC + RAM | FN | Response | PFS | Adverse events (grade ≥2) |
|-----|-----|-----|----|-------|---------|----------|-----------|------------------|----|----------|-----|--------------------------|
| 75  | M   | Ad  | 1  | Wild  | Former  | 60       | +         | 2nd              | - | PR       | 2.4 | Anemia (G2)               |
| 75  | F   | Sq  | 1  | Wild  | Never   | 50       | +         | 7th              | - | SD       | 4.4 | Thrombocytopenia (G3)     |
| 75  | M   | Ad  | 1  | Wild  | Former  | 60       | -         | 2nd              | + | PD       | 1.8 | Neutropenia (G4), anemia (G2), thrombocytopenia (G2), anorexia (G2), mucositis (G2) |
| 76  | M   | La  | 1  | Wild  | Former  | 60       | +         | 3rd              | - | SD       | 2.6 | Neutropenia (G4), mucositis (G2) |
| 76  | M   | Ad  | 1  | L858R | Former  | 60       | +         | 7th              | - | SD       | 2.1 | Anemia (G2)               |
| 76  | M   | Ad  | 1  | L858R | Never   | 50       | -         | 4th              | + | NE       | 1.0 | Neutropenia (G4), mucositis (G2) |
| 77  | M   | Sq  | 1  | Wild  | Former  | 60       | +         | 3rd              | - | PR       | 19.2+| Hypertension (G2)         |
| 78  | M   | Sq  | 1  | Wild  | Former  | 60       | +         | 3rd              | - | PR       | 7.3+| Mucositis (G2)            |
| 78  | F   | Ad  | 1  | Del-19| Never   | 50       | +         | 3rd              | - | PR       | 6.6 | Anemia (G2), ILD (G3)     |
| 79  | F   | Ad  | 1  | Wild  | Never   | 50       | +         | 3rd              | - | SD       | 7.4+| Mucositis (G2)            |
| 79  | F   | Ad  | 2  | Wild  | Never   | 60       | +         | 2nd              | - | SD       | 8.5+| Mucositis (G2)            |

Abbreviations: His, histology; PS, performance status; EGFR, epidermal growth factor receptor; DOC, docetaxel; PEG-G-CSF, pegylated-granulocyte-colony stimulating factor; RAM, ramucirumab; FN, febrile neutropenia; PFS, progression-free survival; M, male; F, female; Ad, adenocarcinoma; Sq, squamous cell carcinoma; La, large cell carcinoma; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; G, grade; ILD, interstitial lung disease.
METHODS

Patients

This is a retrospective study of two institutes. We screened all NSCLC patients to identify cases who had received docetaxel plus ramucirumab in Department of Medical Oncology, KCGH and Department of Thoracic Oncology, SCC. Patients’ results were collected using electric medical and radiographic records to take clinical information: age; gender; smoking history; PS; histology; EGFR-mutation or ALK-fusion status; prior therapies before docetaxel plus ramucirumab; and clinical course details. We evaluated the RR, DCR, PFS, OS, and safety, especially FN. This study was approved by the institutional review board of each institute.

Treatment

Intravenous docetaxel (60 mg/m², day 1) plus intravenous ramucirumab (10 mg/kg, day 1) with subcutaneous PEG-G-CSF (3.6 mg, day 2) every 3 weeks was administered until progression or unacceptable toxicities. Initial docetaxel dose of some cases was reduced to 50 mg/m² by the discretion of physicians in charge. In cases with intolerable toxicities, docetaxel dose was reduced to 50 mg/m², 40 mg/m², or 30 mg/m². Furthermore, docetaxel or ramucirumab monotherapy was administered when intolerable toxicities occurred but clinical benefit was obtained by each drug.

Tumor evaluations were performed every 6–9 weeks with computed tomography.

Statistical analysis

Tumor response was evaluated in accordance with the RECIST (version 1.1). The DCR was defined as the rate of CR/PR + SD ≥6 weeks in our study. The PFS was calculated from the date of therapy initiation to disease progression or death. The OS was calculated from the date of therapy initiation to death, and censored at the date of last visit for patients whose deaths could not be confirmed. PFS and OS were analyzed using the Kaplan-Meier method to estimate the median points with 95% CI. Toxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). The statistical analyses were performed using JMP 12 (SAS Institute, Inc., Cary, NC, USA).

Author contributions

Study concept, AH, DH, NN, and NK; Study design, AH and DH; Data acquisition, AH and DH; Quality control of data and algorithms; AH and DH; Data analysis and interpretation, AH, DH, NN, and NK; Statistical analysis, AH and DH; Manuscript preparation, AH and DH; Manuscript editing, AH and DH; Manuscript review, all authors.

ACKNOWLEDGMENTS

We thank Ayami Asakawa, Mizuho Awaki, Suemi Minamihiara, Hiroko Ishikawa and Mamiya Atagi for their assistance, and Mr. David Martin for writing support.

CONFLICTS OF INTEREST

Akito Hata received lecture fee from Chugai, Astra Zeneca, Boeringer Ingehelm, and Eli Lilly. Daijiro Harada has received lecture fees from Ono, Bristol-Myers Squibb, Yakult Honsha, Kyowa Hakko Kirin, AstraZeneca, Nippon Boehringer Ingelheim and Eli Lilly Japan. Toshiyuki Kozuki has received honoraria from Chugai, AstraZeneca, Eli Lilly Japan, Boehringer–Ingelheim, Ono, Bristol-Myers Squibb, Taiho, MSD, Pfizer and Kyowa Hakko Kirin, and research funding from Chugai, AstraZeneca, MSD, and Eli Lilly Japan. Naoyuki Nogami has received honoraria from Astellas, AstraZeneca, Ono, Taiho, Chugai, Eli Lilly, Boehringer Ingelheim and Pfizer. Nobuyuki Katakami received grants from Astra Zeneca, Eisai, Ono, Kyowa Kirin, Shionogi, Daiichi-Sankyo, Taiho, Chugai, Eli Lilly, Boehringer Ingelheim and Pfizer. The other authors declare no conflicts of interest.

GRANT SUPPORT

None.

REFERENCES

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350:2129–2139.

2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasahki H, Fujii Y, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304:1497–1500.

3. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448:561–566.
4. Lee CK, Wu YL, Lord SJ, Inoue A, Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, Gebski V, Gralla RJ, Yang JC. Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. J Clin Oncol. 2015; 33:1958–1965.

5. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, et al; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371:2167–2177.

6. Reck M, Rodriguez-Arbeu D, Robinson AG, Hui R, Csösz T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, et al; KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375:1823–1833.

7. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Waterhouse D, Ready N, Gainor J, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373:123–135.

8. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäusl M, Arrieta O, et al. Nivolumab versus Docetaxel in Advanced Non-Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373:123–135.

9. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387:1540–1550.

10. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, et al; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017; 389:255–265.

11. Inoue T, Tamiya M, Tamiya A, Nakahama K, Taniguchi Y, Shiroyama T, Isa SI, Nishino K, Kumagai T, Kunimasa K, Kimura M, Suzuki H, Hirashima T, et al. Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab. Clin Lung Cancer. 2017; 17:30274–30277.

12. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O’Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010; 28:780–787.

13. Garon EB, Ciuleanu TE, Arrieta O, Prabhak S, Syrigos KN, Goksel T, Park K, Gorbounova V, Kovalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014; 384:665–673.

14. Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N, Nishio M, Ohe Y, Koue T, Nakamura T, Enatsu S, Lee P, Ferry D, et al. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer. 2016; 99:186–193.

15. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24:3187–3205.

16. Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S, Shimazaki R, Ito Y, Tokuda Y, Tumura K. Phase III placebo-controlled, double-blind, randomized trial of pegasparlimom to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer. 2015; 23:1137–1143.

17. Omori Y, Brenabic A, Rajan N, Park J, Enatsu S, Inoue A. QOL and Febrile Neutropenia: Japanese Phase 2 Trial of Docetaxel with/out Antiangiogenic Agent in 2nd Line NSCLC. J Thorac Oncol. 2017; 12:S901. (abstr: P2.03a-022).